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Abstract
Large and comprehensive genomic surveys of head and neck squamous cell carcinomas are now 
greatly increasing our understanding of the diversity of this disease and the key genomic changes, 
which drive these tumors. The results from these studies are beginning to inform the introduction 
of novel therapies for patients with head and neck squamous cell cancers. Here, we review some 
of the key findings from recent genomic studies of head and neck cancers including the most 
comprehensive study to date from The Cancer Genome Atlas Network.
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Introduction
Head and neck squamous cell carcinomas (HNSCC) are the fifth most common malignancy 
world-wide and comprise a diverse set of cancers arising in the upper aerodigestive tract 
mucosa(1). Unlike many other epithelial cancers, the majority of HNSCCs present at a 
locally advanced stage with cervical lymph node metastases. Over 90% of patients are 
treated with curative intent using a combination of surgery, radiation therapy and 
chemotherapy(2). To date, treatment approaches have been dictated by the anatomic site of 
the primary tumor with oral cavity cancers treated primarily with surgical resection and 
pharyngeal and laryngeal tumors with chemoradiation(3). While over one-half of patients 
Correspondence to: Dr. Jennifer R. Grandis, W912 Biomedical Science Tower, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, 
Phone: 412-383-5405, grandisjr@upmc.edu. 
The authors report no relevant conflicts of interest.
HHS Public Access
Author manuscript
Cancer Discov. Author manuscript; available in PMC 2015 September 01.
Published in final edited form as:













are cured with initial therapy, these treatments are highly morbid, and therapeutic options for 
individuals who relapse following initial treatment are limited(4). In the absence of 
information regarding the biologic underpinnings of individual tumors, predictive 
biomarkers have been lacking to guide therapy in both the initial treatment setting and in the 
treatment of relapsed/refractory disease. Establishing robust therapeutic biomarkers in 
HNSCCs has been challenging for several reasons including the heterogeneity of these 
tumors which display diversity in terms of their anatomy, clinical characteristics and in their 
association with conventional risk factors such as tobacco and alcohol exposure as well as 
with infection with the oncogenic Human Papilloma Virus (HPV) and Epstein-Barr Virus 
(EBV)(2, 5). Recent large-scale genomic profiling studies, notably that of The Cancer 
Genome Atlas (TCGA), have shed light on the molecular underpinnings of the diversity of 
HNSCCs. We highlight some of the key insights from this and other studies and the 
implications of these findings on our understanding of HNSCCs and therapeutic approaches.
The Genomic Landscape of non-HPV Driven HNSCCs
Despite advances in surgical approaches, radiotherapy and chemotherapies, treatment 
outcomes for patients with HNSCCs associated with the traditional risk factors of tobacco 
use, alcohol exposure, or both, remain disappointing as compared to patients with HPV-
driven disease(5, 6). This clinical challenge has stimulated genomic studies focusing on this 
high-risk group of patients with the goal of identifying molecular aberrations, which could 
be targeted to improve clinical outcomes. However, at this time there are no agents in 
clinical use in HNSCCs that show enhanced activity associated with a genetic biomarker. 
While EGFR is overexpressed in HNSCC and has been shown to be associated with reduced 
survival, EGFR-directed therapies have not been especially efficacious(7, 8). Cetuximab, a 
monoclonal antibody directed against EGFR, is the only FDA approved targeted 
molecularly targeted agent for HNSCC, but response rates to this agent given as 
monotherapy are approximately 10% and it remains unclear how to predict the subset of 
patients most likely to respond to cetuximab or other EGFR-directed therapies despite a 
large number of studies addressing this topic(7, 9, 10).
Next-generation sequencing studies of non-HPV driven HNSCCs, including the TCGA 
project which characterized nearly 250 of these individuals (TCGA Network, Nature, in 
press), has demonstrated a complex landscape of alterations in gene expression, DNA copy 
number, somatic mutations, gene rearrangements and gene promoter methylation(11–15). 
These tumors are characterized by near-universal loss of TP53 and CKDN2A/RB1 by 
truncating mutation, deletion and/or alternative splicing. A summary of somatic alterations 
in genes regulating a number of key cellular pathways in HPV-negative and HPV-positive 
HNSCCs is presented in Table 1.
Of note, HPV-negative HNSCCs most closely resemble lung squamous cell carcinomas in 
terms of their spectra of genomic alterations and contain statistically enriched mutations and 
copy number alterations in genes regulating many of the same pathways in addition to 
widespread loss of both TP53 and CDKN2A/RB1(16). These include regulation of squamous 
differentiation (NOTCH1, RIPK4, IRF6, TP63), oxidative stress (NFE2L2, KEAP1), WNT 
signaling (AJUBA, FAT1), immune evasion (HLA-A, B2M, TGFBR2) and chromatin 
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remodeling (MLL2, NSD1)(15) (TCGA Network, Nature, in press). While twenty percent of 
HPV-negative HNSCCs in the TCGA cohort displayed amplifications of Receptor Tyrosine 
Kinase (RTK) genes such as EGFR, ERBB2, MET and FGFR1, there were no recurrent 
mutations or fusions in RTK genes which have been associated with dramatic responses to 
small molecule kinase inhibitors in other tumor types such as lung adenocarcinoma. One 
possible exception is oncogenic exon 14 skipping in MET, which was reported in two 
HNSCC cases by TCGA and is found in 4–5% of lung adenocarcinoma and which may be 
associated with sensitivity to MET small molecule inhibitors.
Mutually exclusive mutations in RAS family genes, notably RHOA, KRAS and HRAS, are 
present but infrequently found in HNSCC (6% of TCGA cases), though recurrent mutations 
in RHOA at amino acid position 40 are worth noting; however, the biological significance of 
these RHOA mutations is unclear. Amplification of chromosome 3q, a region containing the 
TP63, SOX2 and PIK3CA genes, is seen in the majority of both HPV-negative and HPV-
positive HNSCCs and PIK3CA mutations are commonly found in both HPV-negative and 
HPV-positive disease, in agreement with prior studies(11, 14, 15, 17).
HPV-negative HNSCCs arise from a number of anatomic sites including the larynx, oral 
cavity and oropharynx and generally occur in the setting of heavy alcohol and/or tobacco 
exposure or, less commonly, in patients without these well-established risk factors. The 
TCGA cohort did not identify any mutated genes specific to an anatomic site, though the 
numbers of cases in each of these categories was insufficient to comprehensively address 
this question. It should be noted that a prior report suggested TERT promoter mutations are 
enriched in tongue cancers(18). In contrast to lung cancers in which many targetable 
genomic alterations have been identified specifically in patients who lack exogeneous 
carcinogen exposure in the form of tobacco, two small studies of HNSCCs arising in HPV-
negative individuals with minimal tobacco or alcohol histories did not identify any recurrent 
kinase alterations(19, 20).
HPV-negative HNSCCs demonstrate clear evidence of molecular diversity, as suggested by 
expression profiling studies which clearly demonstrate diverse biologic subclasses within 
HPV-negative disease including a class of tumors without EGFR amplification and/or 
overexpression, previously termed “atypical” HNSCCs, which consist of approximately 
20% of HPV-negative cases and the vast majority of HPV-positive HNSCCs(21, 22). An 
intriguing mutational pattern identified by TCGA was a subset of HPV-negative HNSCCs 
originating in the oral cavity with few to no copy number alterations was statistically 
enriched for HRAS, CASP8 and PIK3CA mutations and lack of TP53 mutation (TCGA 
Network, Nature, in press).
HPV-Positive HNSCC
It has well accepted that the clinical features of patients with HPV-driven HNSCC are 
distinct from HPV-negative disease. This includes distinct sites of origin of the disease (eg. 
tonsil and base of tongue), younger age and improved relapse-free survival following initial 
definitive treatment. Clinically, an emphasis on protocol development for patients with 
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HPV-driven HNSCCs has consisted largely of de-escalation of standard therapy with a 
lower dose of radiation, more limited resection or de-intensification of chemotherapy.
Initial next-generation sequencing studies of HPV-positive patients confirmed that these 
individuals harbor few genomic alterations in TP53 and/or CDKN2A, presumably due to the 
activity of the HPV E6 and E7 viral oncoproteins(11). These studies also suggested that 
HPV-driven HNSCCs display less genomic complexity as compared to HPV-negative 
disease, though the TCGA and other more recent cohorts did not confirm this finding, 
perhaps due to tobacco use in the HPV-positive individuals in these studies. This possibility 
is supported by the prevalence of both the virally associated Tp*Cp(A/C/T) substitution 
mutation in the HPV-positive individuals as well as CpG transversions, a mutation class 
typically associated with smoking. A major limitation in most studies reported to date has 
been the relatively small numbers of characterized HPV-positive tumors.
HPV-driven HNSCCs are distinct from HPV-negative disease in that they lack focal RTK 
amplifications but do display a higher rate of focal PIK3CA amplification and mutation. 
PIK3CA alterations have been reported as therapeutic biomarkers in this patient population 
based on cell line and patient-derived xenograft studies(14). HPV-associated HNSCCs also 
demonstrate enrichment for copy number gains in TRAF3 and E2F1 and a lack of CCND1 
amplification when compared with HPV-negative disease.
HPV-driven cancers display both mutations and fusions in the FGFR3 gene with mutations 
at position 249 reported at 14% in one study of 50 cases of locoregionally advanced disease 
and FGFR3-TACC3 fusions have been reported in multiple cases by TCGA and other 
groups(15, 23). These two FGFR3 alterations have been associated with therapeutic 
response to FGFR small molecule inhibitors in pre-clinical (24) and clinical studies (25, 26) 
TCGA did not detect any genes displaying statistical enrichment for mutation in HPV-
positive individuals as compared to HPV-negative though B2M truncating mutations most 
closely approached significance. In addition to FGFR3 mutation, other studies have 
identified the RNA helicase DDX3X, which is mutated in medulloblastoma and is a 
regulator of beta-catenin, as a gene more commonly altered in HPV-positive individuals(15). 
HPV-positive disease shares many common altered genes and pathways with HPV-negative 
HNSCC (eg. NOTCH, MLLs, RAS, WNT)(15).
In addition to the genomic context in which HPV resides it has become increasingly clear 
that the virus itself plays an important role in oncogenesis beyond expression of E6 and 
E7(27, 28). Studies of the interaction of HPV with the human genome in HNSCCs have 
shown that HPV may be present in integrated or non-integrated forms, may be associated 
with the presence of absence of ongoing E6/E7 expression and also may be present in 
extrachromosomal elements. Sites of HPV integration are non-random, occurring in gene- 
and micro-RNA-rich areas of the genome as well as in sites, which are commonly associated 
with somatic copy number alterations. HPV integration can have a profound impact on local 
gene structure and function and result in high-level amplifications, gene disruptions, 
alternative splicing, novel gene fusions and changes in global promoter methylation and 
transcription. An intriguing finding in the field of HPV integration is recurrent disruptive 
integration in the RAD51 gene, perhaps facilitating further HPV integration by hindering 
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DNA repair(29). While the study of host genome-HPV interactions is still maturing it is 
clear that the role of HPV extends beyond the production of E6 and E7 in HNSCCs.
A very important feature of the TCGA data and other cohorts is the demonstration that HPV 
may be detected in HNSCCs using a number of methods including mass spectrometry and 
massively parallel RNA and DNA sequencing and that these methods are far more sensitive 
than those currently applied in the clinic. These methods identify patients without 
conventional clinical features (e.g. larynx cancers, p16 negative) who appear to have HPV-
driven disease. As next-generation sequencing methods are increasingly applied in the clinic 
it will be a challenge moving forward to further define the sensitivity and specificity of these 
newer methods for HPV detection and if there is any significance related to quantitative 
differences in the amount of HPV detected in a given tumor. While p16 
immunnohistochemistry is a simple assay, these recent studies suggest that it should not be 
regarded as an appropriate surrogate for direct assessment of HPV status. p16 assessment 
alone will misclassify individuals in whom HPV is present in the absence of E6/E7 
expression, and more importantly, will overlook HPV in tumors in which both HPV in 
present and in which p16 is lost by an independent mechanism, an especially relevant issue 
in patients with both HPV and a tobacco history. For studies moving forward it will be 
critical to accurately determine HPV status by direct measurement of HPV to avoid 
systematic errors in patient classification and stratification.
Genomics to Targeted Therapeutics
The application of targeted therapeutics in HNSCCs has been disappointing to date as 
compared to other cancer types. This has been due in part to the slower development of 
therapeutic biomarkers and a lack of understanding of the genome landscape of these 
diseases. As noted above, cetuximab is the only targeted agent approved for HNSCC and its 
use in the metastatic setting is associated with a low response rate of 10–15% and most 
studies have failed to find an association between EGFR expression and/or gene 
amplification with response to EGFR inhibitors including cetuximab in HNSCC cohorts. 
There are no prospectively validated biomarkers to enable the selection of patients for 
EGFR-directed therapy.
Prior to the TCGA and other recent studies, earlier reports noted the prevalence of a number 
of genomic alterations in HNSCCs, which are associated with therapeutic response to 
targeted agents in other cancers types. These include EGFR mutations and ALK and ROS1 
fusions. It is now clear that these events are extremely rare in HNSCC, if present at all, and 
that the therapeutic opportunities in HNSCCs more closely resemble squamous cell cancers 
from other tissue types. A few specific examples are discussed below.
Fibroblast Growth Factor Receptors
FGFRs have been shown to be activated by amplification, mutation and translocation in a 
wide range of cancer types. In HNSCC FGFR1 amplifications are found in HPV-negative 
patients at a rate of approximately 10% and appear to be enriched in non-oropharynx 
tumors. FGFR1 amplification has been associated with therapeutic response to FGFR TKIs 
in lung squamous cell cancers, though response rates represent only a modest improvement 
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as compared to chemotherapy(30–32). Multiple explanations for this disappointing result 
have been reported including the presence of co-mutations activating the RAS/MAPK 
pathway, a lack of correlation with FGFR1 amplification and expression or activation of the 
protein and difficulty in standardizing assays for detection of amplification by FISH or NGS 
methods. Several early-phase clinical trials are ongoing or planned in HNSCC patients with 
FGFR1 amplifications who have relapsed/refractory HNSCC (eg. NCT01962532, 
NCT01004224, NCT01948297) though no public data have been reported on efficacy. 
Given that FGFR inhibitors appear to be well-tolerated and may also be radiosensitizers, the 
combination of these agents in the curative treatment setting with the current standard of 
care may be reasonable in high-risk HPV-negative patients.
FGFR2 and FGFR3 mutations and FGFR3-TACC3 fusions are of particular interest as these 
genetic lesions have been associated with dramatic responses to FGFR TKIs in pre-clinical 
models and in early phase clinical settings including a case report of a dramatic response to 
pazopanib in a patient with a FGFR2 mutated tongue cancer(24). In contrast to FGFR1 
amplification, FGFR2/3 mutations and FGFR3 fusions appear to occur largely in HPV-
positive individuals at a prevalence of 10–20% and clinical trials are currently targeting this 
patient population. However, given that these trials are focusing on patients with relapsed/
refractory disease they may encounter difficulty with accrual as the number of HPV-positive 
patients who are candidates for such studies is small.
PI3K/AKT Pathway
PIK3CA is commonly amplified and/or mutated in patients with HNSCCs (37% of cases in 
TCGA), and PIK3CA alterations are enriched in HPV-positive patients. If one examines the 
PI3K/AKT/mTOR pathway in detail more than one-half of patients with HNSCC have a 
somatic alteration, which can activate this pathway. As such, there is tremendous interest in 
developing small molecule inhibitors of components of this pathway for individuals with 
HNSCC and ample pre-clinical data suggest that this may be an effective therapeutic 
strategy, though it should be noted that the activity of PI3K inhibitors as monotherapy in 
lung squamous cell cancers in patients with PIK3CA or PTEN mutations has been 
disappointing. However, initial data have been more encouraging when combining these 
agents with chemotherapy or other targeted agents.
Clinical concepts moving forward include both recruiting patients with relapsed/refractory 
disease with PI3K pathway lesions as well as using these agents in “window of opportunity” 
trials in the up-front setting or in combination with chemoradiotherapy (eg, NCT01816984, 
NCT01195922, NCT01852292, NCT01133678). Pre-clinical data have shown that 
inhibition of the PI3K pathway may sensitize cancer cells to radiation and that PI3K 
inhibitors may be most efficacious as radiosensitizers in patients with NFE2L2 or KEAP1 
mutations, genomic events commonly seen in high-risk HPV-negative individuals(33). A 
clinical trial in this high-risk population is now ongoing based on these pre-clinical data 
(NCT02113878).
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In the TCGA study 32% of HNSCCs displayed an amplification or mutation of CCDN1, 
CDK4 or CDK6 with the majority of these alternations found in HPV-negative patients. It 
should be noted that the genomic region on chromosome 11 containing the CCND1 locus 
also contains other cancer-related genes such as FADD and it is not clear that CCND1 is the 
focus of amplification in all cases with chromosome 11q13 amplification. However, 
impressive early clinical data in breast cancer have suggested that CDK4/6 inhibitors may be 
effective in patient cohorts with high rates of CCND1 amplification and that these agents are 
well-tolerated as both single agents and in combination with other therapies. Clinical trials 
are moving forward at this time in other cancer types with frequent alterations of CCND1/
CDK4/CDK6 and a subset of these trials will include patients with relapsed/refractory 
HNSCC (NCT02101034). Many HPV-negative patients with CCND1/CDK4/CDK6 
amplifications also harbor RTK amplifications, suggesting that combination strategies may 
be needed in this setting.
Immunotherapy
Immunotherapy approaches have garnered a great deal of excitement in the oncology 
community based on the early clinical success of immune checkpoint inhibitors in 
melanoma, renal cell carcinoma and lung cancer. Trials of immunotherapeutic agents are 
ongoing in HNSCC in both the initial treatment setting with ipilimumab and for recurrent 
disease with agents targeting the PD1:PDL1 checkpoint and other immune effectors (eg. 
NCT01860430, NCT01935921) with promising data presented recently with pembrolizumab 
in relapsed/refractory disease(34). PDL1 expression is a biomarker reported by some groups 
to enrich for response to blockade of the PD1:PDL1 checkpoint, and it has been reported in 
other cancer types, including lymphoma and gastric cancer, that PDL1 expression is 
associated with virally-induced cancers(35). While there are several reports on this topic in 
HNSCCs with variable results, RNA sequencing data from TCGA are consistent with higher 
levels of PDL1 expression in HPV-negative individuals. However, it should be noted that 
these samples contain both tumor and stroma and it is still unclear what the optimal methods 
are for PDL1 measurement in the context of patient stratification. In addition to variable 
expression of PDL1, HNSCCs display a wide range of somatic alterations in genes involved 
in antigen presentation, inflammation and immune evasion including HLA-A, B2M, TGFBR2 
and TRAF3. While the mechanisms governing immune evasion in HNSCCs remain poorly 
understood it is likely that somatic alterations in these and other genes are likely to play a 
key role in immune surveillance of HNSCCs and may impact the responsiveness of cancers 
to specific immunotherapeutic approaches. One particular pathway of interest in this regard 
is PI3K given reports in other cancer types that it may be associated with response to 
PD1:PDL1 checkpoint inhibitor therapy(36).
Other targets and strategies
A number of additional therapeutic targets have been proposed for HNSCC based on 
genomic discovery studies and pre-clinical models. HNSCCs frequently display 
hyperactivation of STAT3 via a variety of mechanisms and STAT3 pathway inhibitors are 
currently being explored in both pre-clinical models and in early phase clinical trials. 
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HNSCCs display frequent degregulation of pro- and anti-apoptotic genes such as CASP8 
and cell line studies have suggested that inhibitors of BCL2 family proteins may 
demonstrate activity against HNSCCs. HNSCCs also commonly display concurrent 
amplification of two or more putative “drivers” and pre-clinical studies have demonstrated 
synergy in combining inhibitors in cell lines with demonstrate multiple activated kinase 
pathways such as concurrent EGFR and FGFR pathway activation. Novel EGFR-targeting 
strategies with more potent anti-EGFR TKIs and antibodies are moving forward in HNSCCs 
as are efforts to better define the subset of patients most likely to benefit from anti-EGFR 
therapy.
Conclusions and Recommendations
HNSCCs are less common than other cancer types in which substantial strides in biomarker-
based clinical trials have been made and the number of clinical trials currently available for 
individuals with HNSCCs is approximately one-half the number of trials for patients with 
lung or breast cancers. Further, there are no genetic tests routinely incorporated into the 
management of HNSCC and patient stratification is largely done based on clinical features 
and HPV status. With the widespread incorporation of next-generation sequencing 
diagnostics into the routine care of patients with a wide array of cancer types it will be 
important to consider how this information can be used to improve the efficacy of therapies 
for HNSCCs and here we propose a few possible approaches.
First, the molecular alterations identified in the HNSCC TCGA project and other cohorts are 
not unique and are shared with a number of other epithelial cancer types, most notably lung 
squamous cell carcinoma. We suggest that clinical trials of novel agents in lung SCCs also 
include patients with HNSCCs given this overlap and that “basket trial” approaches be 
considered across these disease types. Natural candidates for this approach include agents 
targeting FGFRs, PIK3K/AKT, CDKs and immunotherapies. Second, HNSCC would seem 
to be an ideal cancer type for “window of opportunity” trials, given the relative accessibility 
of tumor to sample and the widespread use of surgical resection as a standard curative 
approach. In this study approach, a novel agent could be deployed prior to definitive therapy 
to assess its efficacy with biopsy samples taken before and during treatment to identify 
biomarkers of response and resistance. Third, given that we have now defined a number of 
potential targets in HNSCC the use of these agents in the definitive setting with analysis of 
tissue before and after therapy should be conducted so that we might better define cohorts of 
patients for specific therapy approaches in which novel agents may be used in combination 
with chemoradiotherapy in the initial or adjuvant setting. Finally, it will be critical for the 
HNSCC community of Surgeons, Radiation Oncologists and Medical Oncologists to 
appreciate the value of a molecular understanding of HNSCCs to facilitate moving the field 
forward in the era of genomic medicine.
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There has been limited success in the use of targeted therapies of patients with head and 
neck squamous cell carcinomas. Large scale genomic studies have now been conducted 
which have defined the genomic alterations which drive these cancers. The studies have 
demonstrated the unique genomic features and diversity of head and neck squamous cell 
carcinomas and have suggested some initial potential therapeutic targets.
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Table 1
Comparison of the common genomic pathway alterations and of specific genomic alterations by functional 
category in HPV-negative versus HPV-positive HNSCCs.
Genetic Pathways and Alterations HPV− HPV+
RTK Amplification >20% with ERBB family, FGFR, INS1R Rare
RTK mutations/fusions Rare FGFR2/3 mutations in >10%, FGFR3-TACC3 
fusions
H/K/NRAS, NF1 5–10%, HRAS may be most common 5–10%, NF1 loss may be more common
PIK3CA amplification/mutation Common ~30% Very common >50%
TP53 Genomic loss in nearly all cases HPV-driven loss
Cell cycle deregulation Loss of CDKN2A/RB1 by multiple mechanisms in 
nearly all cases, CCND1/CDK4/CDK6 amplification 
common (30%)
HPV-driven CDKN2A loss, E2F1 
amplification (20%)
Oxidative Stress Regulation Common activation of NRF2/KEAP1/CUL3 (25%) Rare
Differentiation Common loss of NOTCH1/FAT1/AJUBA, TP63 
gain
NOTCH1 loss less common, TP63 gain more 
common
Immune evasion Uncommon HLA mutations, <10% HLA, B2M mutations and TRAF3 loss
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